The orphan drug designation is a result of positive findings from a phase 2 clinical trial which demonstrated a 100% clinical benefit rate in patients.
Cullis is known globally for developing the lipid-nanoparticle delivery technology that enables mRNA vaccines, such as those that protect against COVID-19, and other next-generation gene therapies, to work.
Canadian Medical Hall of Fame welcomes Vancouver mRNA innovator Pieter Cullis princegeorgecitizen.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from princegeorgecitizen.com Daily Mail and Mail on Sunday newspapers.
Canadian Medical Hall of Fame welcomes Vancouver mRNA innovator Pieter Cullis richmond-news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from richmond-news.com Daily Mail and Mail on Sunday newspapers.
Canadian Medical Hall of Fame welcomes Vancouver mRNA innovator Pieter Cullis prpeak.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prpeak.com Daily Mail and Mail on Sunday newspapers.